The Canadian Fabry Disease Initiative (CFDI) study is being conducted by a consortium of clinical researchers at five collaborating centres across Canada.  The objective of the CFDI study is to gather additional information regarding the use of enzyme replacement therapies to treat patients suffering from Fabry Disease.

The CFDI study is funded for three years through a joint partnership of Health Canada, participating provincial governments and the private sector. The Canadian Institutes of Health Research (CIHR), as the Government of Canada's health research funding agency, is responsible for administering the federal funding for the CFDI study.

CIHR and the Fonds de la recherche en santé du Québec (FRSQ) are working with Health Canada and provincial governments to ensure that the CFDI study meets internationally accepted standards of scientific excellence. CIHR and FRSQ arranged for international peer review of the study at the proposal stage and collaborated on the establishment of the Independent Scientific Oversight Committee (ISOC) to monitor, evaluate and communicate publicly the results of the research. More information

CIHR Independent Scientific Oversight Committee (ISOC)

• Members
• Terms of Reference
• Procedures

CFDI Study Annual Progress Reports and ISOC Assessments

• 2006-2007
• 2007-2008
• 2008-2009

Contact:
ISOC Secretariat

Project Manager
Mary Fraser Valiquette
Tel: 613-941-4394
Fax: 613-941-0568
Email: mary.fraservaliquette@cihr-irsc.gc.ca